Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs

iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense

LEXINGTON, MA – August 25, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in hospitalized COVID-19 patients with acute hypoxemia ...

Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization (EUA) filing

LEXINGTON, MA – August 4, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, today anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.  Through the DOD’s Chemical Biological Defense ...